Showing 1 to 1 of 1 results
theguardian.com
🌐 85% Global Worthiness
GSK and Oxford to Research Cancer-Preventing Vaccines
GSK is investing £50 million in a three-year research program with Oxford University to develop cancer vaccines targeting pre-cancerous cells, leveraging advancements in neoantigen identification and mRNA technology.
GSK and Oxford to Research Cancer-Preventing Vaccines
GSK is investing £50 million in a three-year research program with Oxford University to develop cancer vaccines targeting pre-cancerous cells, leveraging advancements in neoantigen identification and mRNA technology.
Progress
44% Bias Score
Good Health and Well-being
Showing 1 to 1 of 1 results